Peptide receptor radionuclide therapy combines somatostatin analogs with a therapeutic radionuclide, such as 177Lu, 90Y, or 212Pb, which emits radiation to selectively target and destroy SSTR2-expressing tumor cells. Here, SSTR2 is linked to neoplasm.